A Study of Ustekinumab in Participants With Active Polymyositis and Dermatomyositis Who Have Not Adequately Responded to One or More Standard-of-care Treatments
Conditions: Polymyositis; Dermatomyositis Interventions: Drug: Ustekinumab 6 mg/kg; Drug: Ustekinumab 90 mg; Drug: Placebo IV; Drug: Placebo SC Sponsor: Janssen Pharmaceutical K.K. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials